A Cost-Utility Analysis of 5 Strategies for the Management of Acute Otitis Media in Children

J Pediatr. 2017 Oct:189:54-60.e3. doi: 10.1016/j.jpeds.2017.05.047. Epub 2017 Jun 28.

Abstract

Objective: To assess whether antimicrobial therapy in young children with acute otitis media reduces time to resolution of symptoms, overall symptom burden, and persistence of otoscopic evidence of infection. We used a cost-utility model to evaluate whether immediate antimicrobial treatment seems to be worthwhile, and if so, which antimicrobial agent is most cost effective.

Study design: We compared the cost per quality-adjusted life-day of 5 treatment regimens in children younger than 2 years of age with acute otitis media: immediate amoxicillin/clavulanate, immediate amoxicillin, immediate cefdinir, watchful waiting, and delayed prescription (DP) for antibiotic.

Results: The 5 treatment regimens, listed in order from least effective to most effective were DP, watchful waiting, immediate cefdinir, immediate amoxicillin, and immediate amoxicillin/clavulanate. Listed in order from least costly to most costly, the regimens were DP, immediate amoxicillin, watchful waiting, immediate amoxicillin/clavulanate, and immediate cefdinir. The incremental cost-utility ratio of immediate amoxicillin compared with DP was $101.07 per quality-adjusted life-day gained. The incremental cost-utility ratio of immediate amoxicillin/clavulanate compared with amoxicillin was $2331.28 per quality-adjusted life-day gained.

Conclusions: In children younger than 2 years of age with acute otitis media and no recent antibiotic exposure, immediate amoxicillin seems to be the most cost-effective initial treatment.

Keywords: acute otitis media; cost; cost effectiveness; delayed prescription; ear infection; utility; watchful waiting.

MeSH terms

  • Acute Disease
  • Anti-Infective Agents / economics
  • Anti-Infective Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Cost-Benefit Analysis
  • Humans
  • Infant
  • Otitis Media / drug therapy*
  • Otitis Media / economics
  • Treatment Outcome

Substances

  • Anti-Infective Agents